Literature DB >> 15840997

Complications and postoperative care in patients undergoing treatment for unruptured intracranial aneurysms.

Minna Niskanen1, Timo Koivisto, Jaakko Rinne, Antti Ronkainen, Sanna Pirskanen, Tapani Saari, Ritva Vanninen.   

Abstract

Endovascular treatment has become a feasible alternative in the management of aneurysmal subarachnoid hemorrhage. After endovascular or surgical treatment of patients with unruptured intracranial aneurysms (UIAs), little is known about the practices of observation or need for intensive care. We analyzed retrospectively perioperative complications that were associated with the procedure and postoperative care in patients undergoing management of UIAs. A total of 53 patients underwent endovascular treatment and 105 patients surgical treatment. Location of the aneurysm was the main determinant of the modality of treatment. In the endovascular group, 34 patients were conscious during the procedure and 19 were under general anesthesia. Six patients in the endovascular and 9 in the surgical group experienced complications during the procedure. After the procedure, complications were more common in the surgical group than in the endovascular group (11 versus 0 patients, P = 0.015). Six of the postoperative complications of surgically treated patients occurred in the intensive care unit. Two patients in the endovascular group and five in the surgical group had major neurologic deficits as a consequence of complications. One surgically treated patient died. Both endovascular and surgical treatment of UIAs carry risks that may result in severe neurologic impairment. Patients should be observed with equal vigilance with either treatment option. Surgical treatment is associated with emergencies that require prompt interventions postoperatively and therefore close observation in an ICU setting may be preferable in patients who have undergone surgical treatment of UIAs. Complications after uneventful endovascular procedures seem to be rare.

Entities:  

Mesh:

Year:  2005        PMID: 15840997     DOI: 10.1097/01.ana.0000163202.33236.ml

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  6 in total

1.  Treatment related morbidity of unruptured intracranial aneurysms: results of a prospective single centre series with an interdisciplinary approach over a 6 year period (1999-2005).

Authors:  Rüdiger Gerlach; Jürgen Beck; Matthias Setzer; Hartmut Vatter; Joachim Berkefeld; Richard Du Mesnil de Rochemont; Andreas Raabe; Volker Seifert
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-08       Impact factor: 10.154

2.  Ideal clipping methods for unruptured middle cerebral artery bifurcation aneurysms based on aneurysmal neck classification.

Authors:  Hong Jun Jeon; So Yeon Kim; Keun Young Park; Jae Whan Lee; Seung Kon Huh
Journal:  Neurosurg Rev       Date:  2015-09-26       Impact factor: 3.042

3.  Effect of endovascular treatment on headache in elderly patients with unruptured intracranial aneurysms.

Authors:  D-Q Gu; C-Z Duan; X-F Li; X-Y He; L-F Lai; S-X Su
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-06       Impact factor: 3.825

4.  Feasibility, procedural morbidity and mortality, and long-term follow-up of endovascular treatment of 321 unruptured aneurysms.

Authors:  S Gallas; J Drouineau; J Gabrillargues; A Pasco; C Cognard; L Pierot; D Herbreteau
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-09       Impact factor: 3.825

5.  Treatments for unruptured intracranial aneurysms.

Authors:  Felipe Gomes de Barros Pontes; Edina Mk da Silva; Jose Cc Baptista-Silva; Vladimir Vasconcelos
Journal:  Cochrane Database Syst Rev       Date:  2021-05-10

6.  Use of second generation supraglottic airway device for endovascular treatment of unruptured intracranial aneurysms: a retrospective cohort.

Authors:  Paola Hurtado; Marta Garcia-Orellana; Sergi Amaro; Enrique Carrero; Federico Zarco; Anna Lopez; Neus Fabregas; Ricard Valero
Journal:  Braz J Anesthesiol       Date:  2021-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.